Actively Recruiting
An Observational Study to Assess Real-world Patient Characteristics, Clinical Course, and Treatment Patterns for Symptomatic Patients With Arrhythmogenic Cardiomyopathy Due To a PlaKoPhilin-2 Pathogenic Variant (PKP2)
Led by Lexeo Therapeutics · Updated on 2025-05-16
40
Participants Needed
6
Research Sites
8 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This research aims to understand the real-world characteristics and clinical progression of patients with arrhythmogenic cardiomyopathy caused by a PlaKoPhilin-2 (PKP2) pathogenic variant. It is an observational study designed to evaluate the clinical burden of PKP2-ACM and monitor changes in important cardiac measures and patient-reported outcomes over time. The study includes two parts: a retrospective review of medical records covering up to two years and a prospective observation period lasting one year. During this time, researchers will assess key heart parameters and track patient-reported symptoms and health resource use to study disease progression without administering any experimental treatments. Participants will be involved for about one year in the prospective part, during which their heart function and arrhythmia events will be monitored through ECGs, imaging, and biomarker tests. Patient questionnaires and clinical data collection will help measure outcomes such as premature ventricular contractions and other cardiac events. Safety and health resource usage will also be observed throughout the study.
CONDITIONS
Brief Title
A Study to Assess Real-world Patient Characteristics and Clinical Course for Symptomatic Patients With PKP2-ACM
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults with a clinical diagnosis of arrhythmogenic cardiomyopathy (ACM) based on the 2010 revised Task Force Criteria
- Documentation of a pathogenic or likely pathogenic truncating variant in the PKP2 gene
- Frequent premature ventricular contractions (PVCs)
- Implantable cardioverter defibrillator (ICD) placed before enrollment
- Left ventricular ejection fraction (LVEF) of 50% or higher for Part A participants
- Left ventricular ejection fraction (LVEF) of 40% or higher for Part B participants
You will not qualify if you...
- Presence of additional pathogenic or likely pathogenic variants beyond PKP2 associated with arrhythmogenic cardiomyopathy
- History of other specified cardiac abnormalities
- New York Heart Association Class IV heart failure symptoms at time of consent
- Previous gene transfer therapy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 1 year
Participants are observed prospectively to evaluate changes in key cardiac parameters and patient-reported outcomes associated with PKP2-ACM progression.
Regular visits during the 12 months of observation
Trial Site Locations
Total: 6 locations
1
Leland Stanford Junior University
Redwood City, California, United States, 94063-3126
Actively Recruiting
2
Johns Hopkins University
Baltimore, Maryland, United States, 21287
Actively Recruiting
3
Northshore University Healthsystem Research Institute
Columbia, Maryland, United States, 21044
Actively Recruiting
4
University of Michigan
Ann Arbor, Michigan, United States, 48109
Actively Recruiting
5
Henry Ford Hospital
Detroit, Michigan, United States, 48202
Actively Recruiting
6
University of Rochester
Rochester, New York, United States, 14642
Actively Recruiting
Research Team
P
Person*: Lexeo Clinical Trials
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here